Status:
RECRUITING
PRecision Oncology Evidence Development in Cancer Treatment - Clinical: PREDiCTc
Lead Sponsor:
British Columbia Cancer Agency
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This pilot clinical trial aims to assess the real world quality of life and survival of patients treated with targeted therapy that has preliminary evidence of efficacy in subjects with advanced rare ...
Detailed Description
In Canada, adoption of new systemic therapies for cancer treatment is a multi-step process. After completion of clinical trials, pharmaceutical companies submit a request for a new drug approval to He...
Eligibility Criteria
Inclusion
- Subject age greater than or equal to 18 years at the time of signature of informed consent.
- Subjects with an incurable malignancy who have been identified to have a rare cancer or rare molecular aberration who is currently receiving Health Canada approved targeted therapy that is not nationally funded
- ECOG 0-2
- Life expectancy of at least 12 weeks
- Adequate hematologic and end organ function for drug treatment per the clinician's assessment
- Asymptomatic or treated brain metastases permitted
- Ability to give informed consent for the study procedures defined in this protocol.
Exclusion
- Treatment with any approved or investigational agent or participation in another clinical trial with therapeutic intent within 14 days prior to enrollment.
- Inability to complete quality of life questionnaires
- Subjects who are felt by the treating clinician to be unfit to proceed with this protocol.
Key Trial Info
Start Date :
June 30 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2028
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04814095
Start Date
June 30 2021
End Date
May 1 2028
Last Update
September 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
BC Cancer
Vancouver, British Columbia, Canada, V5Z4E6